Literature DB >> 22215095

Bacteremia in children with sickle hemoglobinopathies.

Shalu Narang1, Isabel Diana Fernandez, Nancy Chin, Norma Lerner, Geoffrey A Weinberg.   

Abstract

BACKGROUND: Bacteremia is one of the most feared infectious complications of sickle cell disease, and it is associated with a high mortality rate in children. The objective of our study was to investigate the proportion of bacteremia among febrile children with sickle hemoglobinopathies and the clinical factors associated with bacteremia.
METHODS: Clinical and microbiological data from children with sickle hemoglobinopathies being followed up at the Pediatric Hematology Clinic at the University of Rochester Medical Center in Rochester, New York, were retrospectively analyzed. The data were collected from medical records covering the time period of June 1997 to December 2006, which included the periods before and after the introduction of routine heptavalent pneumococcal conjugate vaccine usage. Proportions of positive blood cultures among febrile children, the types of organisms causing bacteremia, and clinical and sociodemographic factors were analyzed by χ and t tests as appropriate.
RESULTS: The overall proportion of positive blood cultures was 3.8%; 1% was considered to yield true pathogens. Pneumococcal bacteremia decreased from 0.7% in the pre-pneumococcal conjugate vaccine-7 era to 0.2% in the post-pneumococcal conjugate vaccine-7 era; however, the difference was not statistically significant. Pathogens other than pneumococcus were responsible for most bacteremic episodes. No clinical or social factors were found to have statistically significant associations with positive blood cultures.
CONCLUSIONS: Approximately 1% of children with sickle hemoglobinopathies with fever have bacteremia despite current penicillin prophylaxis and pneumococcal immunization, although most episodes are due to nonpneumococcal pathogens. Prompt evaluation of such febrile children with sickle hemoglobinopathies remains warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215095     DOI: 10.1097/MPH.0b013e318240d50d

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.

Authors:  Marianne E Yee; Kristina W Lai; Nitya Bakshi; Joanna K Grossman; Preeti Jaggi; Alexander Mallis; Yun F Wang; Robert C Jerris; Peter A Lane; Inci Yildirim
Journal:  Pediatrics       Date:  2022-01-01       Impact factor: 7.124

2.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

3.  Assessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease.

Authors:  Jonathan D Santoro; Leann Myers; Julie Kanter
Journal:  J Pediatr Hematol Oncol       Date:  2016-04       Impact factor: 1.289

4.  Immunogenicity of pneumococcal vaccination in a patient with sickle hemoglobinopathy: a case report.

Authors:  E Leila Jerome Clay; Tierra Burrell; Thomas Belhorn; Rupa Redding-Lallinger
Journal:  Clin Case Rep       Date:  2015-06-05

5.  Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects.

Authors:  Michelle B Ryndak; Krishna K Singh; Zhengyu Peng; Susan Zolla-Pazner; Hualin Li; Lu Meng; Suman Laal
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

6.  Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case-control study.

Authors:  Elena María Rincón-López; María Luisa Navarro Gómez; Teresa Hernández-Sampelayo Matos; David Aguilera-Alonso; Eva Dueñas Moreno; Jesús Saavedra-Lozano; Begoña Santiago García; María Del Mar Santos Sebastián; Marina García Morín; Cristina Beléndez Bieler; Jorge Lorente Romero; Elena Cela de Julián
Journal:  BMC Infect Dis       Date:  2021-08-03       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.